Home > Quotes > HEB

Hemispherx BioPharma, Inc. Stock Quote & Summary Data

HEB 
$0.2101
*  
0.0039
  negative  
1.82%
Get HEB Alerts
*Delayed - data as of May 17, 2013 
Exchange: AMEX
Industry: Health Care
Community Rating:
 
 

Symbol List Views

Stock Details

CHARTS

COMPANY NEWS

STOCK ANALYSIS

FUNDAMENTALS

HOLDINGS

Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.


Don't know the stock symbol? Use the symbol lookup tool.

Alphabetize the sort order of my symbols 
Symbol Lookup
Log in or Register
 Save stocks for next time
 | Sponsored

1 Year Target:
Today's High/Low:  / 
Share Volume:
90 Day Avg. Daily Volume This is the average share volume for the past 50 trading days, for NASDAQ stocks and 90 trading days for Non-NASDAQ stocks. This field allows you to compare today’s trading to the average daily volume. 1,090,270
Previous Close: $ 0.214
52 Week High /Low: $ 1.10 / $ 0.18
Market cap “Market Capitalization” is a measure of the estimated value of the common equity securities of the company or their equivalent. It does not include securities convertible into the common equity securities. “Market Capitalization” is derived from the last sale price for the displayed class of listed securities and the total number of shares outstanding for both listed and unlisted securities (as applicable). NASDAQ does not use this value to determine compliance with the listing requirements. 35,135,003
P/E Ratio: NE
Forward P/E(1y) A widely used stock evaluation measure. For a security, the Price/Earnings Ratio is given by dividing the Last Sale Price by the Average EPS (Earnings Per Share) Estimate for the specified fiscal time period. The forward P/E refers to the value for the next full year.
Earnings Per Share (EPS) The EPS listed on our infoquote and Summary Quote page is "12-mos Rolling". EPS represents the portion of a company's profit allocated to each outstanding share of common stock. Net income (reported or estimated) for a period of time is divided by the total number of shares outstanding (TSO) during that period; See growth rate measures for EPS. Our vendor's methodology for the EPS on the infoquote and Summary Quote pages follows the EPS used by the majority of the analysts following the stock, in many cases this is EBITDA EPS. $ -0.11
Annualized dividend N/A
Ex Dividend Date N/A
Dividend Payment Date N/A
Current Yield 0 %
Beta 0.03

 Intraday Chart

5d | 1m | 6m | 12m | More Charting


 Company Description (as filed with the SEC)

We are a specialty pharmaceutical company based in Philadelphia, Pennsylvania and engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. We were founded in the early 1970s doing contract research for the National Institutes of Health. Since that time, we have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of natural interferon and nucleic acids to enhance the natural antiviral defense system of the human body and to aid the development of therapeutic products for the treatment of certain chronic diseases. We have three domestic subsidiaries BioPro Corp., BioAegean Corp., and Core BioTech Corp., all of which are incorporated in Delaware and are dormant. Our foreign subsidiary is Hemispherx Biopharma Europe N.V./S.A. established in Belgium in 1998, which has minimal activity.  ... More ...  



News Headlines for HEB

Hemispherx Biopharma Announces Financial Results for the Three Months Ended March 31, 2013
5/8/2013 3:53:00 PM - GlobeNewswire
The 5 Dumbest Things on Wall Street This Week: May 3
5/3/2013 8:21:00 AM - TheStreet
An Outrageous, Shameless Act by Hemispherx's Board of Directors
5/1/2013 12:03:00 PM - TheStreet
Biotechs Ramping Up On China's Avian Flu Outbreak
4/8/2013 2:42:00 AM - Seeking Alpha
Hemispherx Biopharma Announces Financial Results for the Year Ended December 31, 2012
3/18/2013 3:23:00 PM - GlobeNewswire